ZACKS·2026-02-02 16:00Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for iBio, Inc. despite lower revenues, with actual results being crucial for stock price movement [1] Earnings Expectations - iBio is expected to report a quarterly loss of $0.08 per share, reflecting a year-over-year change of +83.3% [3] - Revenues are projected to be $0.1 million, down 50% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 3.45% higher in the last 30 days, indicating a reassessment by analysts [4] - A positive Earnings ESP of +27.27% suggests analysts have become more optimistic about iBio's earnings prospects [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - iBio currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, iBio was expected to post a loss of $0.07 per share but actually reported a loss of -$0.11, resulting in a surprise of -57.14% [13] - Over the past four quarters, iBio has only beaten consensus EPS estimates once [14] Industry Comparison - Bristol Myers Squibb is expected to report an EPS of $1.15 for the same quarter, indicating a year-over-year change of -31.1% [18] - Revenues for Bristol Myers are expected to be $12.25 billion, down 0.7% from the previous year [18] - The consensus EPS estimate for Bristol Myers has been revised down by 3.9% in the last 30 days, and it currently has an Earnings ESP of 0.00% [19][20]